CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update
05 nov. 2020 16h05 HE
|
CymaBay Therapeutics, Inc.
CymaBay announces trial design for RESPONSE, a global phase 3 registration study for seladelpar in primary biliary cholangitis (PBC) Results from the ENHANCE phase 3 study evaluating seladelpar for...
CymaBay Announces Study to Evaluate the Potential for GPR119 Agonists to Prevent Hypoglycemia in Type 1 Diabetes
05 nov. 2020 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
02 nov. 2020 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
30 oct. 2020 16h32 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020
01 oct. 2020 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Therapeutics to Present at Upcoming Investor Conferences
03 sept. 2020 16h05 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020
27 août 2020 08h00 HE
|
CymaBay Therapeutics, Inc.
Sustained anti-cholestatic and hepatoprotective effects observed in patients with and without cirrhosisSelf-reported pruritus improved at one year for patients in highest categories of baseline...
CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020
20 août 2020 08h00 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 20, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for...
CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update
10 août 2020 16h01 HE
|
CymaBay Therapeutics, Inc.
FDA lifts all clinical holds on seladelpar Positive topline data announced from ENHANCE Company to reinitiate clinical development of seladelpar for patients with PBC Cash sufficient to fund...
CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
03 août 2020 16h01 HE
|
CymaBay Therapeutics, Inc.
NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...